Clive Stanway – Chief Scientific Officer [Biography]
Tony Raynham – Head of Medicinal Chemistry [Biography]
Tim Hammonds - Head of Biochemistry and High Throughput Screening [Biography]
Clive Stanway PhD
Chief Scientific Officer
Clive is responsible for the research and development activity of CRT. CRT’s laboratory comprises staff who are skilled in molecular and cellular biology, drug discovery, early pharmacology and medicinal chemistry. Prior to the formation of CRT, he was Director of Project Development for Imperial Cancer Research Technology and previously worked leading teams in drug discovery at Prolifix and Xenova. Clive is a graduate of Nottingham University (BSc) and Imperial College (PhD) and worked as a postdoctoral researcher for 9 years in several laboratories at Oxford University.
Tony Raynham, PhD, C.Chem, FRSC
Head of Chemistry
Tony obtained a BSc (Hons) degree in chemistry from Imperial College of Science and Technology, London and a PhD in natural product synthesis from Northwestern University, Illinois, USA. He then worked on developing novel asymmetric synthesis methodologies as a postdoctoral fellow at the University of Geneva before moving to Roche Discovery Welwyn as a medicinal chemist working on drug discovery programs aimed at inhibiting key proteases in cardiovascular and anti-viral therapeutic areas. After a brief spell as a Head of Chemistry at Cambridge Discovery Chemistry, Tony was appointed Associate Director of Oncology Discovery Chemistry at Millennium Pharmaceuticals. During this time, he managed drug discovery programs focussed on the inhibition of novel cell-cycle kinases and novel enzymes within the Ubiquitin-26S Proteasome pathway and developed MLN8054, an inhibitor of Aurora Kinase, currently in Phase 1 clinical trials. Towards the end of 2003 Tony was awarded a Fellowship from the Royal Society of Chemistry and at the beginning of 2004 he moved to CRT to head the Medicinal Chemistry department.
Tim Hammonds, BPharm, PhD.
Head of Biochemistry and High Throughput Screening.
Tim has a degree in Pharmacy and a PhD in pharmaceutical chemistry and microbiology from the University of Nottingham studying the antiviral mechanism of tubulin binding drugs. Following his PhD Tim worked for one year studying the biophysics of DNA-protein interactions in the University of Toronto before returning to the UK at Leicester University to study the enzymology and inhibition of the ATPase of topoisomerase II enzymes. During his PhD and postdoctoral studies Tim was engaged in the transfer of many assay formats, both enzyme and cell-based, to microtitre plates to increase throughput and accuracy. Tim joined CRT in 1999 and currently oversees a team of 10 who develop and miniaturise assays and run HTS campaigns vs. the CRT compound library.
|
